^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Alemtuzumab is recommended in elderly patients with CLL and del(17p) or TP53 mutation.
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:…CLL/SLL with del(17p)/TP53 mutation...Other recommended regimens...Alemtuzumab ± rituximab
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

Excerpt:
Clinical responses in patients with p53 mutations, deletions, or both were noted in 6 (40%) of 15 versus 4 (19%) of 21 of patients without. The median response duration for this subset of patients was 8 months (range, 3-17 months). These data suggest that alemtuzumab may be an effective therapy for patients with CLL with p53 mutations or deletions...
DOI:
10.1182/blood-2003-10-3729